Scholar Rock Holding (SRRK) Cash from Financing Activities (2017 - 2026)
Scholar Rock Holding (SRRK) posted quarterly Cash from Financing Activities of $193.8 million for Q1 2026, up 4548.26% year-over-year from $4.2 million in Q1 2025, and up 164.42% quarter-over-quarter from $73.3 million in Q4 2025.
Analysis
Scholar Rock Holding (SRRK) Cash from Financing Activities (2017 - 2026) Analysis & Trends
Scholar Rock Holding's Cash from Financing Activities history runs 10 years deep, the most recent figure standing at $193.8 million for Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 4548.26% year-over-year to $193.8 million; the TTM figure through Mar 2026 stood at $418.0 million (up 19.2% YoY), while the FY2025 annual figure was $228.4 million, down 35.3% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $193.8 million, up from $73.3 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $346.4 million in Q4 2024, with the low at -$970000.0 in Q4 2022.
- The 5-year median for Cash from Financing Activities is $4.7 million (2023), against an average of $63.1 million.
- The sharpest annual moves came in 2022 and 2025: Cash from Financing Activities tumbled 123.66% in 2022, then jumped 86929.52% in 2025.
- Scholar Rock Holding's Cash from Financing Activities stood at -$970000.0 in 2022, then surged by 10051.44% to $96.5 million in 2023, then soared by 258.82% to $346.4 million in 2024, then slumped by 78.84% to $73.3 million in 2025, then jumped by 164.42% to $193.8 million in 2026.
- Business Quant data shows SRRK's Cash from Financing Activities at $193.8 million in Q1 2026, $73.3 million in Q4 2025, and $144.5 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | 14.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | 2.42 Bn |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | -6.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 36.24 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | -273.15 Mn |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Scholar Rock Holding | 7.19 Bn | 7.19 Bn | - | 83.12 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 83.12 Mn |
| Mar 31, 2026 | 193.79 Mn |
| Dec 31, 2025 | 73.29 Mn |
| Sep 30, 2025 | 144.47 Mn |
| Jun 30, 2025 | 6.47 Mn |
| Mar 31, 2025 | 4.17 Mn |
| Dec 31, 2024 | 346.37 Mn |
| Sep 30, 2024 | 166,000.00 |
| Jun 30, 2024 | -33,000.00 |
| Mar 31, 2024 | 6.53 Mn |
| Dec 31, 2023 | 96.53 Mn |
| Sep 30, 2023 | 280,000.00 |
| Jun 30, 2023 | 4.69 Mn |
| Mar 31, 2023 | 1.08 Mn |
| Dec 31, 2022 | -970,000.00 |
| Sep 30, 2022 | -451,000.00 |
| Jun 30, 2022 | 195.77 Mn |
| Mar 31, 2022 | 481,000.00 |
| Dec 31, 2021 | 39.70 Mn |
| Sep 30, 2021 | 1.91 Mn |